Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milan Radovich

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
The Journal of Clinical Investigation|January 16, 2026
Retraction for Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancerYunhua Liu, Hanchen Xu, Kevin Van der Jeught, et al.
The Journal of Clinical Investigation|May 1, 2026
Amendment to Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancerYunhua Liu, Hanchen Xu, Kevin Van der Jeught, et al.
JCO Precision Oncology|June 8, 2026
Integrated Molecular and Clinical Analysis of Thymic Epithelial TumorsChul Kim, Tolulope Adeyelu, Rohan Maniar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100Bryan P Schneider, Molin Wang, Milan Radovich, et al.
NPJ Breast Cancer|December 20, 2025
Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profilingGeorge W Sledge, Joanne Xiu, Reshma L Mahtani, et al.
The Journal of Molecular Diagnostics : JMD|April 22, 2022
Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome SequencingReynold C Ly, Tyler Shugg, Ryan Ratcliff, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 2026
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapyMilan Radovich, James Wacker, Jeffrey Solzak, et al.
JCO Precision Oncology|January 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast CancersArielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 10, 2024
Evidence for Unified Assessment Criteria of HER2 Immunohistochemistry in Colorectal CarcinomaMark G Evans, Harris B Krause, Joanne Xiu, et al.
Breast Cancer Research : BCR|August 7, 2019
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancersBradley A Hancock, Yu-Hsiang Chen, Jeffrey P Solzak, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
The Journal of Clinical Investigation|January 16, 2026
Retraction for Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancerYunhua Liu, Hanchen Xu, Kevin Van der Jeught, et al.
The Journal of Clinical Investigation|May 1, 2026
Amendment to Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancerYunhua Liu, Hanchen Xu, Kevin Van der Jeught, et al.
JCO Precision Oncology|June 8, 2026
Integrated Molecular and Clinical Analysis of Thymic Epithelial TumorsChul Kim, Tolulope Adeyelu, Rohan Maniar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100Bryan P Schneider, Molin Wang, Milan Radovich, et al.
NPJ Breast Cancer|December 20, 2025
Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profilingGeorge W Sledge, Joanne Xiu, Reshma L Mahtani, et al.
The Journal of Molecular Diagnostics : JMD|April 22, 2022
Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome SequencingReynold C Ly, Tyler Shugg, Ryan Ratcliff, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 2026
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapyMilan Radovich, James Wacker, Jeffrey Solzak, et al.
JCO Precision Oncology|January 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast CancersArielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 10, 2024
Evidence for Unified Assessment Criteria of HER2 Immunohistochemistry in Colorectal CarcinomaMark G Evans, Harris B Krause, Joanne Xiu, et al.
Breast Cancer Research : BCR|August 7, 2019
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancersBradley A Hancock, Yu-Hsiang Chen, Jeffrey P Solzak, et al.
Pageof 11